These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 29648886)

  • 1. BRAF Adds an Additional Piece of the Puzzle to Precision Oncology-Based Treatment Strategies in Lung Cancer.
    Planchard D; Johnson BE
    Arch Pathol Lab Med; 2018 Jul; 142(7):796-797. PubMed ID: 29648886
    [No Abstract]   [Full Text] [Related]  

  • 2. An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib.
    Abravanel DL; Nishino M; Sholl LM; Ambrogio C; Awad MM
    J Thorac Oncol; 2018 Aug; 13(8):e131-e133. PubMed ID: 29631033
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report.
    Reyes R; Mayo-de-Las-Casas C; Teixidó C; Cabrera C; Marín E; Vollmer I; Jares P; Garzón M; Molina-Vila MÁ; Reguart N
    Clin Lung Cancer; 2019 May; 20(3):e219-e223. PubMed ID: 30926357
    [No Abstract]   [Full Text] [Related]  

  • 4. Durable Response to Combination of Dabrafenib and Trametinib in BRAF V600E-Mutated Non-small-cell Lung Cancer.
    Pervere LM; Rakshit S; Schrock AB; Miller VA; Ali SM; Velcheti V
    Clin Lung Cancer; 2017 May; 18(3):e211-e213. PubMed ID: 28024926
    [No Abstract]   [Full Text] [Related]  

  • 5. Response of BRAF
    Yamamoto G; Sakakibara-Konishi J; Ikari T; Kitai H; Mizugaki H; Asahina H; Kikuchi E; Shinagawa N
    J Thorac Oncol; 2019 May; 14(5):e97-e99. PubMed ID: 31027751
    [No Abstract]   [Full Text] [Related]  

  • 6. Dabrafenib Active in Rare NSCLC Subtype.
    Cancer Discov; 2016 Jul; 6(7):OF4. PubMed ID: 27207893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeated complete response with long-term control of BRAF-mutant melanoma by multiple rechallenges with dabrafenib plus trametinib.
    Sasaki K; Nakamura Y; Baba N; Teramoto Y; Yamamoto A
    Eur J Cancer; 2020 Nov; 139():37-40. PubMed ID: 32957012
    [No Abstract]   [Full Text] [Related]  

  • 8. Steroid refractory dermatomyositis following combination dabrafenib and trametinib therapy.
    Harrison SR; Tew A; Steven N; Fisher BA
    Rheumatology (Oxford); 2018 Aug; 57(8):1497-1499. PubMed ID: 29617934
    [No Abstract]   [Full Text] [Related]  

  • 9. Complete response for 36 months after BRAF and MEK inhibitor therapy for locally advanced gallbladder melanoma.
    Hakim S; Orosey M; Edhi A; Amin M; Cappell MS
    Minerva Gastroenterol Dietol; 2019 Sep; 65(3):243-246. PubMed ID: 31115206
    [No Abstract]   [Full Text] [Related]  

  • 10. BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors.
    Roque A; Odia Y
    CNS Oncol; 2017 Apr; 6(2):95-99. PubMed ID: 28425764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TTF-1 positive posterior pituitary tumor: Limitations of current treatment and potential new hope in BRAF V600E mutation variants.
    Dawoud FM; Naylor RM; Giannini C; Swanson AA; Meyer FB; Uhm JH
    Clin Neurol Neurosurg; 2020 Sep; 196():106059. PubMed ID: 32682222
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination therapy of dabrafenib plus trametinib in patients with BRAF
    Rizzo A; Ricci AD; Brandi G
    Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):506-507. PubMed ID: 33334695
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of BRAF-mutated metastatic melanoma].
    Boyles TB; Svane IM; Bastholt L; Schmidt H
    Ugeskr Laeger; 2016 Aug; 178(35):. PubMed ID: 27592869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conjunctival Melanoma Responsive to Combined Systemic BRAF/MEK Inhibitors.
    Dagi Glass LR; Lawrence DP; Jakobiec FA; Freitag SK
    Ophthalmic Plast Reconstr Surg; 2017; 33(5):e114-e116. PubMed ID: 27893585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple Therapy Improves Colorectal Cancer Response.
    Cancer Discov; 2016 Dec; 6(12):OF6. PubMed ID: 27770002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dabrafenib plus trametinib in patients with previously untreated BRAF
    Planchard D; Smit EF; Groen HJM; Mazieres J; Besse B; Helland Å; Giannone V; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE
    Lancet Oncol; 2017 Oct; 18(10):1307-1316. PubMed ID: 28919011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.
    Dhillon S
    Target Oncol; 2016 Jun; 11(3):417-28. PubMed ID: 27246822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dabrafénib and tramétinib in BRAF V600E mutated pediatric gliomas].
    Giorgis O; Doz F
    Bull Cancer; 2024 May; 111(5):429-430. PubMed ID: 38471994
    [No Abstract]   [Full Text] [Related]  

  • 19. A rare BRAF T599dup mutation conferring sensitivity to BRAF inhibitor in a patient with metastatic melanoma.
    Marchand A; Tallet A; Collin C; Cormier B; Venel Y; Miquelestorena-Standley E; Machet L
    Br J Dermatol; 2018 Aug; 179(2):528-529. PubMed ID: 29494756
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.